Status:
COMPLETED
Incidence of Psoriatic Arthritis Among Psoriasis Patients Newly Initiated With Secukinumab in a US Claims Database and a UK Registry
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Psoriatic Arthritis
Psoriasis
Eligibility:
All Genders
18+ years
Brief Summary
This was a retrospective cohort study to assess the incidence rate of psoriatic arthritis (PsA) among psoriasis (PsO) patients newly initiated on secukinumab or any biologics/apremilast (small molecul...
Eligibility Criteria
Inclusion
- MarketScan® secukinumab cohort:
- Inclusion criteria:
- Included patients with at least 1 secukinumab claim between 01 January 2015 and 30 June 2020 (index date is the first secukinumab claim)
- Included patients age ≥18 years as of the year of index date
- Included patients with at least 1 non-ruleout psoriasis diagnosis during 2 years of pre-index period
- Included patients with continuous medical/pharmacy coverage in the 2-year pre-index period
- Included patients with continuous medical/pharmacy coverage in the 1-year post-index period
- Exclusion criteria:
- Excluded patients with any psoriatic arthritis diagnosis during 2 years to 5 years pre-index period, as well as on the index date
- Excluded patients with any biologics/apremilast including secukinumab claim during the 2-year pre-index (excluding index date)
- Excluded patients received other non-secukinumab biologics/apremilast during 6 months post index date period (including index date) (This criterion is only applicable for the secukinumab cohort)
- BADBIR cohort:
- Inclusion criteria:
- Included non-switched patients with secukinumab treatment on or after the enrollment between 01 January 2017 to 01 September 2020
- Non-switched patients are those who did not use other biologics/apremilast treatments on the enrollment date
- Index date will be the date of the first secukinumab treatment date
- Included patients with age ≥ 18 on the index date
- Included patients with psoriasis diagnosis in the pre-index period and index date
- Included patients with ≥ 1 year follow-up period
- Follow-up period is the gap between patient's last visit date and index date
- Exclusion criteria:
- Excluded patients with psoriatic arthritis (PsA) prior to and on index date
- Excluded patients with any biologics/apremilast including secukinumab in the baseline period
Exclusion
Key Trial Info
Start Date :
November 17 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 7 2022
Estimated Enrollment :
1171 Patients enrolled
Trial Details
Trial ID
NCT06172426
Start Date
November 17 2022
End Date
December 7 2022
Last Update
December 15 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis
Basel, Switzerland, 4002